GSK: Cancer claims plague pharma giant as it settles another Zantac case February 29, 2024 GSK has reached another confidential settlement in a Californian lawsuit that had alleged its best-selling indigestion drug, Zantac, was carcinogenic.
Haleon reports single-digit growth in revenue after year of disposals February 29, 2024 Its revenue went up by four per cent from £10.8bn reported in 2022, as the company's adjusted operating profit had a healthy growth of 10.4 per cent, at constant currency to £2.5bn.
GSK reports robust results from latest trial with injectable HIV treatment February 21, 2024 GSK has today reported favourable findings from the Latitude phase III study of its long-acting injectable antiretroviral treatment (ART) for HIV. The study was conducted by Viiv Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders. The company said that an interim analysis of the Latitude [...]
GSK snaps up potential asthma treatment gamechanger in £800m deal February 15, 2024 GSK has completed the acquisition of Aiolos Bio, a company working on treatments for respiratory and inflammatory conditions.
GSK receives Fast Track designation for chronic hepatitis B drug in latest boost for pharma giant February 12, 2024 Pharmaceutical giant GSK has received a special recognition from the US Food and Drug Administration (FDA) for its bepirovirsen drug.
GSK announces breakthrough with blood cancer treatment drug Blenrep February 6, 2024 Biotech giant GSK has announced a potential breakthrough in the treatment of relapsed or refractory multiple myeloma, a type of blood cancer.
FTSE 100 close: Bluechip index closes lower as investors await Fed’s interest rate decision January 31, 2024 London’s FTSE 100 closed in the red as investors await the latest interest rate decision from the US Federal Reserve later today, while big tech results last night soured risk sentiment. The FTSE 100 ended 0.47 per cent lower at 7,630.57 while the midcap FTSE 250 index, which is more aligned with the health of [...]
GSK split seems to be paying off as vaccines drive upgraded profit guidance January 31, 2024 "We are now planning for at least 12 major launches from 2025, with new Vaccines and Specialty Medicines for infectious diseases, HIV, respiratory and oncology," Emma Walmsley, chief executive at GSK said.
GSK spin-off Haleon offloads Chapstick brand for £400m to ‘simplify’ business January 25, 2024 Consumer healthcare company Haleon has agreed to sell its Chapstick lip balm brand to Yellow Wood Partners in a deal worth $510m (£401m) as part of efforts to "simplify" its business model.
GSK to spend up to £1.1bn in deal for access to unique asthma treatment January 9, 2024 GSK, formerly known as Glaxosmithkline, has agreed to acquire biopharmaceutical company Aiolos Bio in a deal worth at least $1bn (£785m), as it hails access to the latter company's twice-yearly asthma treatment.